VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know

VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know

---

---

Abstract

This paper provides a comprehensive review of VEXAS syndrome; a newly recognized, adult-onset autoinflammatory condition with a genetic basis and complex multisystem involvement, carrying significant implications for hematologists, rheumatologists, and other specialists. First described in 2020, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic mutations in the UBA1 gene, which plays a critical role in the ubiquitin-proteasome system. These mutations disrupt protein degradation and immune regulation, resulting in chronic inflammation and hematologic abnormalities.

The clinical course is often progressive and treatment-resistant, overlapping with conditions such as relapsing polychondritis, Sweet’s syndrome, and myelodysplastic syndromes (MDS). Diagnosis requires a high index of suspicion, especially in adult males with systemic inflammatory symptoms, hematologic abnormalities, and resistance to conventional immunosuppressive therapies. There is currently no standardized treatment, and management remains challenging.

By reviewing the latest evidence, this paper aims to increase awareness and understanding of VEXAS syndrome among medical practitioners, potentially leading to improved patient outcomes through earlier diagnosis and more targeted interventions.

---

Introduction

VEXAS syndrome, identified in 2020, is a rare, adult-onset autoinflammatory disorder with significant clinical implications, particularly for hematologists. The acronym VEXAS stands for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic, each representing key features of the disease. It is caused by somatic mutations in the UBA1 gene, located on the X chromosome, which encodes the E1 enzyme involved in ubiquitination. These mutations disrupt protein degradation pathways, leading to systemic inflammation and bone marrow dysfunction.

Primarily affecting men over the age of 50, VEXAS presents with a wide array of symptoms, including recurrent fevers, chondritis, vasculitis, pulmonary infiltrates, and cutaneous manifestations such as neutrophilic dermatoses. Hematologic abnormalities are a hallmark of the disease and may include macrocytic anemia, thrombocytopenia, and progression to myelodysplastic syndromes (MDS) or other bone marrow disorders. Bone marrow biopsy often reveals cytoplasmic vacuoles in myeloid and erythroid precursors, a distinguishing feature of the syndrome.

VEXAS syndrome is challenging to diagnose due to its overlap with other rheumatologic, hematologic, and dermatologic conditions. Definitive diagnosis requires genetic testing for somatic UBA1 mutations, often through next-generation sequencing (NGS).

Currently, treatment options are limited and largely supportive. High-dose glucocorticoids remain the mainstay for controlling inflammation, though responses are often partial or transient. Immunosuppressants such as methotrexate, azacitidine, and JAK inhibitors have been used with variable success. Allogeneic stem cell transplantation is under investigation as a potential curative approach in select patients.

Given its complex clinical presentation and serious outcomes, VEXAS syndrome demands a high index of suspicion among clinicians. This paper aims to equip hematologists and healthcare providers with a clear understanding of the syndrome’s genetic basis, clinical spectrum, diagnostic strategies, and evolving treatment landscape to support timely recognition and effective management.

 

Genetic Basis of VEXAS Syndrome

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a late-onset autoinflammatory disorder driven by somatic mutations in the UBA1 gene, which resides on the X chromosome. The UBA1 gene encodes ubiquitin-activating enzyme E1, a key initiator of the ubiquitin-proteasome system—a fundamental pathway responsible for protein degradation, turnover, and regulation of various cellular processes, including inflammation and immune responses.

The pathogenic mutations in VEXAS affect hematopoietic stem and progenitor cells, resulting in genetic mosaicism; a coexistence of mutated and non-mutated cell populations. This somatic mosaicism is central to the disease’s heterogeneity, contributing to its wide range of clinical manifestations, severity, and disease progression among patients.

Notably, these mutations are not inherited but acquired later in life, explaining the adult onset of the syndrome. Most identified mutations alter the Met41 codon of UBA1, leading to defective E1 enzyme function and dysregulation of protein homeostasis, which drives chronic inflammation and bone marrow abnormalities characteristic of the disorder.

 

Clinical Presentation

VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a complex, multi-system disorder characterized by both inflammatory and hematologic features. Its presentation is highly variable, often involving several organ systems simultaneously, which can complicate diagnosis.

Hematologic Findings:

• Macrocytic anemia is one of the hallmark features, often refractory to standard treatment.
• Thrombocytopenia may also be present, contributing to bleeding risk.
• Many patients develop features consistent with myelodysplastic syndrome (MDS), particularly with multilineage dysplasia.

Inflammatory Manifestations:

• Recurrent fevers and systemic inflammation are common and may mimic autoimmune or infectious processes.
• Polyarthritis, often symmetrical, may resemble rheumatoid arthritis.
• Chondritis, especially of the ears and nose, is frequently observed and can mimic relapsing polychondritis.

Dermatologic Involvement:

• Neutrophilic dermatoses, including Sweet syndrome-like eruptions, are frequent.
• Cutaneous vasculitis and painful skin ulcers are also seen, sometimes with histopathologic evidence of leukocytoclastic vasculitis.

Pulmonary Involvement:

• Lung findings may include pulmonary infiltrates and diffuse alveolar hemorrhage, which can be life-threatening.

Constitutional Symptoms:

• Patients often report profound fatigue, unintentional weight loss, and night sweats, contributing to decreased quality of life.

The clinical course is typically chronic and progressive, with considerable variation in symptom severity and organ involvement. Diagnosis requires a high index of suspicion, especially in adult males presenting with unexplained inflammation and cytopenias, and is confirmed through detection of somatic mutations in the UBA1 gene.

 

Diagnostic Approach

Diagnosing VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome requires a structured and multidisciplinary approach, integrating clinical evaluation, laboratory findings, imaging, bone marrow analysis, and genetic testing. The goal is to identify hallmark clinical features and confirm the presence of somatic mutations in the UBA1 gene, which are central to diagnosis.

1. Clinical Assessment

The diagnostic process begins with a thorough clinical evaluation:

• Detailed medical history, including onset, duration, and progression of symptoms
• Physical examination, focusing on systemic inflammatory signs
• Multisystem symptom review, particularly for features such as fevers, chondritis, skin rashes, pulmonary involvement, vasculitis, and arthritis

2. Laboratory Investigations

Routine and specialized tests help identify inflammatory and hematologic abnormalities:

• Complete blood count (CBC) with differential, often showing macrocytic anemia, leukopenia, or thrombocytopenia
• Inflammatory markers, including elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
• Liver and kidney function tests, to assess end-organ involvement
• Autoantibody screening, to rule out other autoimmune or autoinflammatory conditions

3. Imaging Studies

Imaging is used to evaluate organ involvement and guide further testing:

• Chest X-ray or CT scan, especially for pulmonary infiltrates or effusions
• Musculoskeletal imaging (e.g., MRI, ultrasound) when joint inflammation is suspected

4. Bone Marrow Examination

Bone marrow analysis is critical in detecting hematologic features of VEXAS:

• Aspiration and biopsy, often revealing cytoplasmic vacuoles in myeloid and erythroid precursors
• Cytogenetic and morphologic evaluation, to assess for myelodysplasia or other clonal hematologic disorders

5. Genetic Testing

The definitive diagnosis relies on molecular confirmation:

• Sequencing of the UBA1 gene, performed on peripheral blood or bone marrow samples
• Detection of somatic mutations, typically affecting hematopoietic stem and progenitor cells

 

Treatment Approaches

Currently, there is no curative therapy for VEXAS syndrome. Treatment focuses on controlling symptoms, managing complications, and improving quality of life. Therapeutic decisions are tailored to each patient’s clinical presentation, disease severity, and overall health.

• Immunosuppressive Therapy

Immunosuppressive agents are commonly used to reduce inflammation and control disease activity:

• Corticosteroids (e.g., prednisone) remain a mainstay for acute symptom control.
• Conventional immunosuppressants such as methotrexate, cyclosporine, and tacrolimus may be used as steroid-sparing agents or adjuncts.

• Biologic and Targeted Therapies

For patients with refractory or severe inflammation, biologics and small molecule inhibitors may offer additional benefit:

• TNF-α inhibitors (e.g., infliximab, adalimumab)
• IL-1 inhibitors (e.g., anakinra, canakinumab)
• JAK inhibitors (e.g., tofacitinib), particularly useful given the somatic UBA1 mutation’s role in dysregulated immune signaling

• Supportive Care

Supportive interventions address hematologic complications and reduce morbidity:

• Red blood cell transfusions for symptomatic anemia
• Platelet transfusions for severe thrombocytopenia or bleeding risk
• Infection management, including prompt identification and treatment, given the immunosuppressed state

• Hematopoietic Stem Cell Transplantation (HSCT)

HSCT may be considered in select patients, particularly younger individuals with life-threatening or refractory disease. While not curative, it offers a potential for long-term disease control in carefully selected cases.

Regular monitoring is essential to assess treatment response, manage adverse effects, and adjust therapy as needed. A multidisciplinary approach involving hematology, rheumatology, and infectious disease specialists is often required to optimize outcomes.

 

Challenges and Future Directions

Managing VEXAS syndrome presents several complexities that hinder timely diagnosis and effective treatment:

• Limited Clinical Awareness: As a recently identified condition, VEXAS remains underrecognized among many healthcare providers, contributing to diagnostic delays.
• Heterogeneous Presentation: The syndrome manifests with a wide range of inflammatory and hematologic symptoms, making it difficult to distinguish from other autoimmune or myelodysplastic conditions.
• Absence of Standardized Treatment Guidelines: Currently, there is no consensus on optimal therapeutic strategies. Management is largely empirical, often requiring off-label use of immunosuppressants or cytotoxic agents.
• High Risk of Misdiagnosis: Overlapping clinical features with other disorders can lead to incorrect or delayed diagnoses, particularly in settings without access to advanced genetic testing.

Future Research Priorities
Addressing these challenges will require a coordinated research effort focused on the following areas:

• Genetic Characterization: Expanding our understanding of additional genetic modifiers and somatic mutations that influence disease severity and progression.
• Targeted Therapeutic Development: Designing treatments that specifically address the UBA1 mutation or downstream inflammatory pathways implicated in VEXAS pathogenesis.
• Gene-Based Interventions: Investigating the potential of gene therapy or genome editing as long-term solutions, especially in patients with refractory disease.
• Global Data Collection: Establishing international patient registries to facilitate large-scale studies, identify prognostic markers, and guide evidence-based clinical practice.

Together, these efforts will support earlier diagnosis, more effective therapies, and improved long-term outcomes for patients living with VEXAS syndrome.

 

---

Conclusion

VEXAS syndrome represents a significant addition to the spectrum of hematological and autoinflammatory disorders. Its recognition has important implications for patient care, particularly in the fields of hematology, rheumatology, and dermatology. By increasing awareness and understanding of VEXAS syndrome, healthcare professionals can improve their ability to diagnose and manage this complex disorder effectively.

Key points to remember:

1. Genetic basis: VEXAS syndrome is caused by somatic mutations in the UBA1 gene on the X chromosome.
2. Clinical presentation: The disorder is characterized by a triad of hematological, inflammatory, and dermatological symptoms.
3. Diagnosis: A combination of clinical evaluation, laboratory testing, and genetic analysis is required for definitive diagnosis.
4. Treatment: Management focuses on symptom control and addressing specific complications, with no current curative treatment available.
5. Challenges: Limited awareness, variable presentation, and lack of standardized treatment protocols pose significant challenges in managing VEXAS syndrome.

Summary of important aspects:

• VEXAS syndrome primarily affects older adults, particularly men.
• The condition often presents with macrocytic anemia, recurrent fevers, and skin manifestations.
• Diagnosis requires a high index of suspicion and genetic testing for UBA1 mutations.
• Treatment approaches include immunosuppressive therapy, biologic agents, and supportive care.
• Hematopoietic stem cell transplantation may be considered in select cases.

As research into VEXAS syndrome continues, it is likely that our understanding of its pathogenesis, clinical features, and optimal management strategies will evolve. Future research directions may include:

• Identifying additional genetic factors influencing disease expression
• Developing targeted therapies based on the underlying genetic defect
• Exploring the role of gene therapy or genome editing approaches
• Establishing international registries to improve understanding of long-term outcomes

Hematologists and other medical practitioners should stay informed about these developments to provide the best possible care for patients with this newly discovered condition. Ongoing education and collaboration across medical specialties will be crucial in advancing our knowledge and improving outcomes for individuals affected by VEXAS syndrome.

 

Frequently Asked Questions:

1. Q: How common is VEXAS syndrome?

   A: VEXAS syndrome is considered a rare disorder, but its exact prevalence is not yet known. It is likely underdiagnosed due to limited awareness and variable clinical presentation.

2. Q: Why does VEXAS syndrome primarily affect older men?

   A: The X-linked nature of the UBA1 gene mutations explains the male predominance. The late onset may be related to the accumulation of somatic mutations over time in hematopoietic stem cells.

3. Q: Can women develop VEXAS syndrome?

   A: While VEXAS syndrome predominantly affects men, cases in women have been reported. The presentation in women may be milder due to the presence of two X chromosomes.

4. Q: Is VEXAS syndrome inherited?

   A: VEXAS syndrome is not typically inherited. It is caused by somatic mutations that occur during a person’s lifetime, rather than being present from birth.

5. Q: How is VEXAS syndrome different from other autoinflammatory disorders?

   A: VEXAS syndrome is unique in its combination of hematological abnormalities, inflammatory features, and specific genetic mutation in the UBA1 gene. This distinguishes it from other autoinflammatory conditions.

6. Q: What is the long-term prognosis for patients with VEXAS syndrome?

   A: The long-term prognosis varies among patients. Some individuals respond well to treatment, while others may experience progressive disease. More research is needed to understand long-term outcomes fully.

7. Q: Can VEXAS syndrome be cured?

   A: Currently, there is no cure for VEXAS syndrome. Treatment focuses on managing symptoms and complications. Hematopoietic stem cell transplantation may offer a potential cure in select cases, but more research is needed.

8. Q: How can healthcare professionals stay updated on VEXAS syndrome research?

   A: Healthcare professionals can stay informed by following relevant medical journals, attending conferences, and participating in continuing medical education programs focused on rare hematological and autoinflammatory disorders.

 

 

---

References:

Beck, D. B., Ferrada, M. A., Sikora, K. A., Ombrello, A. K., Collins, J. C., Pei, W., … & Kastner, D. L. (2020). Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. New England Journal of Medicine, 383(27), 2628-2638.

Georgin-Lavialle, S., Terrier, B., Guedon, A. F., Heiblig, M., Comont, T., Lazaro, E., … & Quartier, P. (2022). Diagnosis and management of VEXAS syndrome: expert opinion of the Société Nationale Française de Médecine Interne (SNFMI). Orphanet Journal of Rare Diseases, 17(1), 1-12.

Koster, M. J., Kourelis, T., Reichard, K. K., Kermani, T. A., Parikh, K., Abril, A., … & Warrington, K. J. (2022). Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clinic Proceedings, 97(4), 696-704.

Ferrada, M. A., Sikora, K. A., Luo, Y., Wells, K. V., Patel, B., Groarke, E. M., … & Grayson, P. C. (2021). Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis & Rheumatology, 73(6), 991-995.